We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1946
Completed
100.0%
No approval data available
- A Kookmin University-led team integrated genomic, transcriptomic, epigenomic, proteomic, and phosphoproteomic data from over 100 medulloblastoma patients to refine the conventional four molecular groups into seven distinct subtypes. - The SHHβ and G4γ subtypes showed enhanced neuronal differentiation and relatively favorable outcomes, while SHHα, G4α, and G4β were linked to higher risk of recurrence and progression. - Researchers identified subtype-specific protein signaling pathways and potential therapeutic targets, laying groundwork for precision medicine-based targeted therapies. - The findings, published in Experimental & Molecular Medicine, address the poor survival rates after medulloblastoma recurrence and the need for molecularly guided treatment.